Effect of mouse VEGF164 on the viability of hydroxyethyl methacrylate-methyl methacrylate-microencapsulated cells in vivo: Bioluminescence imaging

Journal of Biomedical Materials Research - Part A

Volumn 87, Issue 2, 2008, Pages 321-331

  Cheng, Dangxiao ^a   Lo, Chuen ^a   Sefton, Michael V ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bioluminescent imaging; HEMA MMA; Microencapsulation; Tissue engineering; Vascularization

Indexed keywords

BIOLUMINESCENCE; ESTERS; LUMINESCENCE;

BIOLUMINESCENT IMAGING; HEMA-MMA; MICROENCAPSULATION; TISSUE ENGINEERING; VASCULARIZATION;

ENCAPSULATION;

2 HYDROXYETHYL METHACRYLATE; LUCIFERASE; LUCIFERIN; MATRIGEL; METHACRYLIC ACID METHYL ESTER; POLY(HYDROXYETHYL CO METHYL METHACRYLATE); UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR 164; VASCULOTROPIN; BIOMATERIAL; FIREFLY LUCIFERASE; LUMINESCENT AGENT; METHACRYLIC ACID DERIVATIVE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CELL COUNT; CELL VIABILITY; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMAGING SYSTEM; IN VIVO STUDY; MICROENCAPSULATION; NONHUMAN; OXYGEN TRANSPORT; ANGIOGENESIS; ANIMAL; C3H MOUSE; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; CULTURE MEDIUM; DRUG EFFECT; DRUG FORMULATION; EVALUATION; GENETICS; IMPLANT; MALE; MATERIALS TESTING; METABOLISM; METHODOLOGY; MOUSE; TISSUE ENGINEERING;

ANIMALS; BIOCOMPATIBLE MATERIALS; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CULTURE MEDIA, CONDITIONED; DRUG COMPOUNDING; HUMANS; IMPLANTS, EXPERIMENTAL; LUCIFERASES, FIREFLY; LUMINESCENT AGENTS; MALE; MATERIALS TESTING; METHACRYLATES; METHYLMETHACRYLATES; MICE; MICE, INBRED C3H; NEOVASCULARIZATION, PHYSIOLOGIC; TISSUE ENGINEERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 53549088623     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.31716     Document Type: Article

References (40)

1. Dionne KE, Colton CK, Yarmush ML. Effect of hypoxia on insulin secretion by isolated rat and canine islets of Langerhans. Diabetes 1993;42:12-21.
2. Sutherland RM. Cell and environment interactions in tumor microregions: The multicell spheroid model. Science 1988;240:177-184.
3. Avgoustiniatos ES, Colton CK. Effect of external oxygen mass transfer resistances on viability of immunoisolated tissue. Ann N Y Acad Sci 1997;831:145-167.
4. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932-936.
5. Peters MC, Polverini PJ, Mooney DJ. Engineering vascular networks in porous polymer matrices. J Biomed Mater Res 2002;60:668-678.
6. Vallbacka JJ, Sefton MV. Vascularization and improved in vivo survival of VEGF-secreting cells microencapsulated in HEMA-MMA. Tissue Eng 2007;13:2259-2269.
7. Ormiston M, Sefton MV. Secretable alkaline phosphatase (SEAP) as a measure of in vivo microencapsulated cell viability, in preparation.
8. Shima DT, Kuroki M, Deutsch U, Ng Y, Adamis AP, D'Amore PA. The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J Biol Chem 1996;271:3877-3883.
9. McColm JR, Geisen P, Hartnett, ME. VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. Mol Vis 2004;10:512-520.
10. Sefton MV, Hwang JR Babensee JE. Selected aspects of the microencapsulation of mammalian cells in HEMA-MMA. Ann N Y Acad Sci 1997;831:260-270.
11. Feng M Sefton MV. Hydroxyethyl methacrylate-methyl methacrylate (HEMA-MMA) copolymers for cell microencapsulation: Effect of HEMA purity. J Biomater Sci Polym Ed 2000;11:537-545.
12. Dvorak HF. Discovery of vascular permeability factor (VPF). Exp Cell Res 2006;312:522-526.
13. Sun Y, Jin K, Xie L, Childs J, Mao XO, Logvinova A, Greenberg DA. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest 2003;111:1843-1851.
14. Chang DS, Su H, Tang GL,. Brevetti LS, Sarkar R, Wang R, Kan YW, Messina LM. Adeno-associated viral vector-mediated gene transfer of VEGF normalizes skeletal muscle oxygen tension and induces arteriogenesis in ischemic rat hindlimb. Mol Ther 2003;7:44-51.
15. Ferrarini M, Arsic N, Recchia FA, Zentilin L, Zacchigna S, Xu X, Linke A, Giacca M, Hintze TH. Adeno-associated virus-mediated transduction of VEGF165 improves cardiac tissue viability and functional recovery after permanent coronary occlusion in conscious dogs. Circ Res 2006;98:954-961.
16. Zhang ZG, Zhang L, Jiang Q, Zhang R, Davies K, Powers C, Bruggen N, Chopp M. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain, J Clin Invest 2000;106:829-838.
17. Benton RL, Whittemore SR. VEGF165 therapy exacerbates secondary damage following spinal cord injury. Neurochem Res 2003;28:1693-1703.
18. Kastrup J. Therapeutic angiogenesis in ischemic heart disease: Gene or recombinant vascular growth factor protein therapy? Curr Gene Ther 2003;3:197-206.
19. Carmeliet P Conway EM. Growing better blood vessels. Nature 2001;19:1019-1020.
20. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9:685-693.
21. Pandya NM, Dhalla NS, Santani DD. Angiogenesis-a new target for future therapy. Vasc Pharmacol 2006;44:265-274.
22. Richardson TP, Peters MC, Ennett AB, Mooney DJ. Polymeric system for dual growth factor delivery. Nat Biotechnol 2003;19:1029-1034.
23. Peirce SM, Price RJ, Skalak TC. Spatial and temporal control of angiogenesis and arterialization using focal applications of VEGF164 and Ang-1. Am J Physiol Heart Circ Physiol 2004;286:H918-H925.
24. Ajioka I, Akaike T, Watanabe Y. Expression of vascular endothelial growth factor promotes colonization, vascularization, and growth of transplanted hepatic tissues in the mouse. Hepatology 1999;29:396-402.
25. Suzuki K, Murtuza B, Smolenski RT, Sammut IA, Suzuki N, Kaneda Y, Yacoub MH. Cell transplantation for the treatment of acute myocardial infarction using vascular endothelial growth factor-expressing skeletal myoblasts. Circulation 2001;104(12 Suppl 1):I207-I212.
26. De Coppi P, Delo D, Farrugia L, Udompanyanan K, Yoo JJ, Nomi M, Atala A, Soker S. Angiogenic gene-modified muscle cells for enhancement of tissue formation. Tissue Eng 2005;11:1034-1044.
27. Chae HY, Lee BW, Oh SH, Ahn YR, Chung JH, Min YK, Lee MS, Lee MK, Kim KW. Effective glycemic control achieved by transplanting non-viral cationic liposome-mediated VEGF-transfected islets in streptozotocin-induced diabetic mice. Exp Mol Med 2005;37:513-523.
28. Yau TM, Kim C, Li G, Zhang Y, Fazel S, Spiegelstein D, Weisel RD, Li RK. Enhanced angiogenesis with multimodal cell-based gene therapy. Ann Thorac Surg 2007;83:1110-1119.
29. Rinsch C, Quinodoz P, Pittet B, Alizadeh N, Baetens D, Montandon D, Aebischer P, Pepper MS. Delivery of FGF-2 but not VEGF by microencapsulated genetically engineered myoblasts improves survival and vascularization in a model of acute skin flap ischemia. Gene Ther 2001;8:523-533.
30. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-248.
31. Springer ML, Hortelano G, Bouley DM, Wong J, Kraft PE, Blau HM. Induction of angiogenesis by implantation of microencapsulated primary myoblasts expressing vascular endothelial growth factor. J Gene Med 2000;2:279-288.
32. Ozawa CR, Banfi A, Glazer NL, Thurston G, Springer ML, Kraft PE, McDonald DM, Blau HM. Microenviromental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest 2004;113:516-527.
33. Yokomori H, Oda M, Yoshimura K, Nagai T, Ogi M, Nomura M, Ishii H. Vascular endothelial growth factor increases fenestral permeability in hepatic sinusoidal endothelial cells. Liver Int 2003;23;467-475.
34. Le Cras TD, Spitzmiller RE, Albertine KH, Greenberg JM, Whitsett JA, Akeson AL. VEGF causes pulmonary hemorrhage, hemosiderosis, and air space enlargement in neonatal mice. Am J Physiol Lung Cell Mol Physiol 2004;287:L134-L142.
35. Carmeliet P. VEGF gene therapy: Stimulating angiogenesis or angioma-genesis? Nat Med 2000;6:1102-1103.
36. Weissleder R. A clearer vision for in vivo imaging. Nat Biotechnol 2001;19:316-317.
37. Sadikot RT, Blackwell TS. Bioluminescence imaging. Proc Am Thorac Soc 2005;2:537-540.
38. Fowler M, Virostko J, Chen Z, Poffenberger G, Radhika A, Brissova M, Shiota M, Nicholson WE, Shi Y, Hirshberg B, Harlan DM, Jansen ED, Powers AC. Assessment of pancreatic islet mass after islet transplantation using in vivo bioluminescence imaging. Transplantation 2005;79:768-776.
39. Wilson T, Hastings JW. Bioluminescence. Annu Rev Cell Dev Biol 1998;14:197-230.
40. Rice BW, Cable MD, Nelson MB. In vivo imaging of light-emitting probes. J Biomed Opt 2001;6:432-440.